SAN FRANCISCO, October 30, 2025 — Leads & Copy — Counterpart Health, a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), has released a whitepaper demonstrating how its Counterpart Assistant (CA) technology supports value-based care in high Area Deprivation Index (ADI) neighborhoods. The analysis shows that CA’s clinical technology supports early detection, disease progression tracking, and proactive interventions.
Key findings from the whitepaper include higher diagnosis rates for diabetes, chronic kidney disease (CKD), chronic heart failure (CHF), and chronic obstructive pulmonary disease (COPD) among patients from socioeconomically disadvantaged neighborhoods. Patients with CKD or diabetes were diagnosed at earlier clinical stages of disease. CA PCP attribution was associated with less acute care utilization, including fewer all-cause inpatient hospitalizations and 30-day readmissions.
Dr. David Tsay, Chief Medical Officer at Counterpart Health, stated that early detection opens a critical window for intervention and can fundamentally change disease trajectories. Conrad Wai, CEO of Counterpart Health, added that CA addresses the gap in data and technology infrastructure needed to deliver effective, value-based care. The whitepaper is Counterpart’s sixth retrospective data analysis measuring CA’s clinical impact.
Investor Relations: Ryan Schmidt, investors@cloverhealth.com
Press Inquiries: press@cloverhealth.com
Source: Counterpart Health
